ROCKVILLE, Md., Sept. 23, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that an oral presentation highlighting the use of the Company's AutoloGel™ System to effect rapid healing of chronic wounds in patients with spinal cord injury (SCI) was presented at the Academy of Spinal Cord Injury Professionals' Annual Meeting being held September 22-24, 2010 in Las Vegas, Nevada. This meeting is supported by the Paralyzed Veterans of America.
The AutoloGel System is a device for the production of autologous platelet rich plasma ("PRP") gel and is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use on a variety of exuding wounds. Its patent-protected formulation provides physiologically relevant concentrations of PRP that are optimal for wound healing.
The presentation, entitled "Response of Wounds of Spinal Cord Injury Patients to Autologous Platelet Rich Plasma Gel", was delivered by Laurie Rappl, PT, CWS of the Cytomedix Clinical Team during the Session, "Secondary Complications of SCI," on Wednesday, September 22, 2010 from 1:30 - 3:00 p.m. (local time). This presentation detailed a prospective case series of 13 wounds in 10 patients, showing rapid healing in wound area and volume, as well as reduction of undermining and sinus tracts/tunnels in non-healing wounds. Details of the case series can be obtained by contacting Ms. Rappl at lrappl@cytomedix.com.
Commenting on the presentation, Martin P. Rosendale, President and CEO of Cytomedix, Inc., said, "It is particularly rewarding for Cytomedix to be highlighting the rapid healing achieved by our AutoloGel System for the treatment of chronic wounds in SCI patients. Pressure ulcers and other chronic wounds are a persistent medical challenge that compromises the health and quality of life for these paralyzed patients. Our clinical data demonstrates how the AutoloGel System's physiologically relevant concentrations of PRP can rapidly restart the healing process in complex and chronic wounds, including wounds that were recalcitrant to other treatments."
About the Academy of Spinal Cord Injury Professionals
The Academy of Spinal Cord Injury Professionals is the premier, interdisciplinary organization dedicated to advancing the care of people with spinal cord injury/dysfunction (SCI/D). The Academy's Annual meeting is the premier conference for spinal cord injury/dysfunction professionals, including more than 800 leaders, the "best and the brightest," in SCI/D health care and research. The meeting features more than 20 continuing education units, and is a world-class venue for SCI/D professionals to network, share ideas, and to integrate the disciplines of medicine, nursing, psychology, social work, behavioral health, and rehabilitation therapy.
About Paralyzed Veterans of America
For 64 years, Paralyzed Veterans of America and its 34 chapters have been working to create an America where all veterans and people with disabilities, and their families, have everything they need to thrive. The organization was founded by a band of spinal cord injured service members who returned home from World War II to a grateful nation, but also to a world with few solutions to the challenges they faced. They made a decision not just to live, but to live with dignity as contributors to society. They created an organization dedicated to veterans' service, medical research, and civil rights for people with disabilities.
Today, Paralyzed Veterans of America represents more than 19,000 veterans in all 50 states, the District of Columbia, and Puerto Rico. With world-class clinical practice guidelines and companion consumer guides and such publications as Yes, You Can! A Guide to Self-Care for Persons with Spinal Cord Injury, Paralyzed Veterans of America continually strives to empower clinicians and patients alike, and they have invested more than $100 million in research for treatments and a cure for paralysis.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma and platelet rich plasma ("PRP") in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at .
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Cytomedix, Inc. David Jorden, Executive Board Member Martin Rosendale, CEO Andrew Maslan, CFO (240) 499-2680 Lippert/Heilshorn & Associates Anne Marie Fields (212) 838-3777 (afields@lhai.com) Bruce Voss (310) 691-7100 (bvoss@lhai.com)